Actos Bellwether Cases Scheduled for MDL 2299

shutterstock_563916787Presiding Judge Rebecca Doherty has issued a detailed schedule for proceedings in the Actos Multidistrict Litigation (MDL) 2299.

Bellwether trials, which are typical in MDLs, are early trials designed by both parties to gauge the juries’ reactions to evidence. The trials picked as bellwether cases normally represent egregious cases. Attorneys can then understand how future trials might proceed.

The Bellwether trials in this Actos case are set for November 3rd, 2014, and January 12th, 2015, respectively. Judge Doherty will issue a more complete test trial protocol by October 31st, 2012. Attorneys will finish selecting 20 cases as potential bellwether trials by June 3rd, 2013, and by October 16th, 2013, the test trials will be selected.

Currently, 300 cases have been filed in MDL 2299, but thousands more are expected. The FDA issued a new warning label for Actos in June 2011, after France and Germany both pulled Actos from the market because of a link between the diabetes drug and bladder cancer. The drug, manufactured by Takeda Pharmaceuticals, is linked not only to bladder cancer, but to an increased risk of diabetic macular edema, a vision disorder that eventually leads to blindness. Patients with Type 2 diabetes have a high risk of many disorders, including bladder cancer, but Actos seems to make the complications of Type 2 diabetes much worse.

If you or a loved one have taken Actos to treat Type 2 diabetes, and have developed bladder cancer or congestive heart failure, you may be entitled to compensation. The lawyers at Strom Law, LLC, have experience with Actos lawsuits, and can help you get the money you need for lost wages and future medical expenses. We are now accepting cases against Takeda Pharmaceuticals nationwide. Please contact us today for a free consultation, to get you on the road to recovery. 803.252.4800.

Share:

Share on facebook
Facebook
Share on twitter
Twitter
Share on linkedin
LinkedIn
Categories
Archives

Follow us

Sign Up For Our Newsletter!